Simultaneous Session

THALIDOMIDE MAINTENANCE SIGNIFICANTLY IMPROVES PROGRESSION FREE (PFS) BUT NOT OVERALL SURVIVAL (OS) OF MYELOMA PATIENTS, WITH PFS BENEFITS IN FAVOURABLE FISH SUBGROUPS ONLY: MRC MYELOMA IX RESULTS
A Child, F Davies, W Gregory, K Cocks, S Bell, A Szubert, N Navarro Coy, M Drayson, R Owen, F Ross, G Jackson, G Morgan (Clinical Trials Research Unit, Leeds, United Kingdom)

IMPACT OF UPFRONT BORTEZOMIB-BASED REGIMENS ON CLINICAL OUTCOMES OF NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS ACCORDING TO CYTOGENETIC ABNORMALITIES BY FISH ANALYSIS
M Cavo, A Palumbo, S Bringhen, F Di Raimondo, F Patriarca, D Rossi, A Levi, M Offidani, V Montefusco, F Narni, R Zambello, G Benevolo, M Grasso, A Falcone, P Musto, T Guglielmelli, F Gherlinzoni, D Gottardi, C Musolino, N Di Renzo, L Masini, C Cangialosi, F Dore, S Ballanti, S Storti, E Angelucci, R Vallone, V Magarotto, F Morabito, P Tosi, M Boccadoro (Istituto di Ematologia „Seragnoli„, Bologna, Italy)

BORTEZOMIB PLUS DEXAMETHASONE VERSUS REDUCED-DOSE BORTEZOMIB PLUS THALIDOMIDE-DEXAMETHASONE AS INDUCTION PRIOR TO AUTOLOGOUS TRANSPLANTATION IN NEWLY DIAGNOSED MYELOMA
JL Harousseau, H Avet-Loiseau, J Mary, T Facon, M Attal, C Doyen, C Hulin, L Garderet, M Tiab, G Lepeu, C Araujo, D Caillot, M Petillon, C Mathiot, P Moreau (Rene Gauducheau Cancer Center, Nantes/St Herblain, France)

FINAL DONOR VERSUS NO DONOR COMPARISON OF NEWLY DIAGNOSED MYELOMA PATIENTES INCLUDED IN THE HOVON 50/54 STUDY
H Lokhorst, P Sonneveld, B van der Holt, M Kersten, M van Oers, R Raymakers, M Minnema, S Zweegman, J Janssen, G Bos, G Huls, E Vellinga, M Schaap, J Zijlmans (University Medical Center Utrecht, Utrecht, The Netherlands)

RESULTS OF PX-171-00, AN ONGOING OPEN-LABEL, PHASE II STUDY OF CARFILZOMIB IN PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (R/R MM) WITH OR WITHOUT PRIOR BORTEZOMIB EXPOSURE
K Stewart, D Siegel, M Wang, J Kaufman, A Jakubowiak, S Jagannath, V Kukreti, K McDonagh, M Alsina, N Bahlis, A Belch, N Gabrail, M Le, M Bennett, R Vij, The MM Research Consortium (Mayo Clinic, Scottsdale, USA)

TRANSGENIC MICE EXPRESSING A JAK2 EXON 12 MUTATION DISPLAY ISOLATED ERYTHROCYTOSIS CLOSELY RESEMBLING THE HUMAN JAK2 EXON 12 POLYCYTHEMIA
S Li, H Hao-Shen, R Tiedt, R Skoda (University Hospital Basel, Basel,

PEGYLATED INTERFERON-ALFA (IFNA) 2A TREATMENT TARGETS JAK2V617F CLONES WITHOUT AFFECTING TET2 MUTANT CELLS IN POLYCYTHEMIA VERA (PV)
JJ Kiladjian, A Massé, B Cassinat, H Mokrani, I Teyssandier, JP Le Couédic, N Cambier, C Almire, E Pronier, N Casadevall, W Vainchenker, C Chomienne, F Delhommeau (Hopital Saint-Louis, Paris, France)

V617F MUTATION INDUCES NUCLEAR LOCALIZATION OF JAK2 IN CD34+ CELLS BUT NOT GRANULOCYTIC, MEGAKARYOCYTIC OR ERYTHROID CELLS OF PATIENTS WITH PHILADELPHIANEGATIVE MYELOPROLIFERATIVE DISORDERS
CR Rinaldi, P Rinaldi, V Senyuk, N Esposito, G Nucifora, F Pane (Federico II University, Naples, Italy)

SIGNALING PATTERNS IN MYELOPROLIFERATIVE NEOPLASMS SEGREGATE WITH DISEASE PHENOTYPE RATHER THAN JAK2 GENOTYPE
S Anand, F Stedham, P Beer, E Gudgin, A Bench, W Erber, A Green, B Huntly (Cambridge Institute of Medical Research, University of Cambridge, Cambridge, United Kingdom)

OVEREXPRESSION OF TRANSCIPTION FACTOR NF-E2 IN VIVO CAUSES A MYELOPROLIFERATIVE DISORDER WITH EXPANSION OF THE STEM CELL COMPARTMENT
B Kaufmann, A Gruender, R Bogeska, M Gothwal, H Pahl (University Hospital Freiburg, Freiburg, Germany)

ACQUIRED MUTATIONS IN THE GENES ENCODING IDH1 AND IDH2 BOTH ARE RECURRENT ABERRATIONS IN ACUTE MYELOID LEUKEMIA (AML): PREVALENCE AND PROGNOSTIC VALUE
S Abbas, S Lugthart, F Kavelaars, A Schelen, J Koenders, A Zeilemakers, W van Putten, A Rijneveld, B Löwenberg, P Valk (ErasmusMC, Rotterdam, The Netherlands)

PROGNOSTIC IMPACT OF ISOCITRATE DEHYDROGENASE ENZYME ISOFORMS 1 (IDH1) AND 2 (IDH2) MUTATIONS IN ACUTE MYELOID LEUKEMIA. A STUDY BY THE ACUTE LEUKEMIA FRENCH ASSOCIATION (ALFA) GROUP
O Nibourel, N Boissel, A Renneville, C Gardin, O Reman, N Contentin, D Bordessoule, C Pautas, T Revel, B Quesnel, N Philippe, S Geffroy, P Huchette, C Terre, X Thomas, S Castaigne, H Dombret, C Preudhomme (CHRU Lille, Lille, France)

IDH1 AND IDH2 GENE MUTATIONS IDENTIFY NOVEL MOLECULAR SUBSETS WITHIN DE NOVO CYTOGENETICALLY NORMAL ACUTE MYELOID LEUKEMIA (CN-AML): A CANCER AND LEUKEMIA GROUP B (CALGB) STUDY
G Marcucci, K Maharry, YZ Wu, M Radmacher, K Mrózek, D Margeson, K Holland, S Whitman, H Becker, S Schwind, K Metzeler, B Powell, T Carter, J Kolitz, M Wetzler, M Baer, A Carroll, M Caligiuri, R Larson, C Bloomfield (The Ohio State University, Columbus, USA)

IDH1 AND IDH2 GENE MUTATIONS ARE FREQUENT MOLECULAR LESIONS IN ACUTE MYELOID LEUKEMIA (AML) AND CONFER ADVERSE PROGNOSIS IN CYTOGENETICALLY NORMAL AML WITH NPM1 MUTATION WITHOUT FLT3-ITD
P Paschka, R Schlenk, V Gaidzik, M Habdank, J Krönke, L Bullinger, D Späth, S Kayser, M Zucknick, K Götze, H Horst, U Germing, H Döhner, K Döhner (University Hospital of Ulm, Ulm, Germany)

IDH1 MUTATIONS ARE DETECTED IN 6.6% OF ALL AML AND ARE STRONGLY ASSOCIATED WITH INTERMEDIATE RISK KARYOTYPE AND UNFAVOURABLE PROGNOSIS: A STUDY OF 1414 PATIENTS
S Schnittger, C Haferlach, U Ulke, T Tamara, W Kern, T Torsten (MLL Munich Leukemia Laboratory, Munich, Germany)

MAJOR MOLECULAR RESPONSE RATE AT ONE YEAR IS HIGHER IF PEGYLATED INTERFERON ALPHA-2B IS ADDED TO IMATINIB IN NON-HR CHRONIC MYELOID LEUKEMIA PATIENTS IN IMATINIB INDUCED COMPLETE HEMATOLOGICAL REMISSION
B Simonsson, M Gedde-Dahl, M Markevärn, P Remes, R Stentoft, S Almqvist, T Björeman, V Flogegård, U Hallman, L Koskenveesa, A Lindblom, C Malm, S Mustjoki, K Myhr-Eriksson, A Räsänen, M Sinisalo, R Sippola, A Själander, U Strömberg, O Weiss Bjerrum, H Ehrencrona, F Gruber, V Kairisto, K Olsson, F Sandin, A Nagler, J Lanng Nielsen, H Hjorth-Hansen, K Porkka (Hematology Unit, University Hospital, Uppsala, Sweden)

TREATMENT OPTIMIZATION BY HIGH DOSE IMATINIB: RANDOMIZED COMPARISON OF IMATINIB 800 MG VS. IMATINIB 400 MG VS. IMATINIB 400 MG + IFN IN NEWLY DIAGNOSED BCR-ABL POSITIVE CHRONIC PHASE (CP) CML WITH REGARD TO MMR AT MONTH 12. THE GERMAN CML-STUDY IV
R Hehlmann, S Jung-Munkwitz, M Lauseker, A Leitner, N Pletsch, U Proetel, M Müller, C Haferlach, B Schlegelberger, S Schnittger, C Waller, A Neubauer, L Kanz, M Hänel, J Mayer, F Stegelmann, R Fuchs, S Koschmieder, L Balleisen, M Pfirrmann, G Ehninger, T Fischer, D Hossfeld, HJ Kolb, S Krause, C Nerl, H Pralle, A Gratwohl, A Tobler, H Heimpel, J Hasford, A Hochhaus, S Saußele, B Hanfstein (Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany)

SIGNIFICANT IMPROVEMENT OF MOLECULAR RESPONSES WITH PEGYLATED FORM OF INTERFERON A2A IN COMBINATION WITH IMATINIB (IM) IN CHRONIC MYELOID LEUKAEMIA (CML) PATIENTS (PTS) REPORT OF A PHASE III TRIAL
F Guilhot, C Preudhomme, J Guilhot, FX Mahon, FE Nicolini, F Rigual-Huget, L Legros, A Guerci, D Rea, V Coiteux, F Maloisel, M Gardembas, C Bulabois, M Berger (INSERM CIC 80, Poitiers, France)

CONTINUED SUPERIORITY OF NILOTINIB VS IMATINIB IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): ENESTND BEYOND 1 YEAR
A Hochhaus, C Lobo, R Pasquini, R Clark, DW Kim, S Issaragrisil, P le Coutre, J Reiffers, H Kantarjian, G Saglio, P Edrich, A Hoenekopp, N Gallagher, R Larson, T Hughes (Universitätsklinikum Jena, Jena, Germany)

NILOTINIB 400 MG BID IN EARLY CHRONIC PHASE PH+ CHRONIC MYELOID LEUKEMIA: RESULTS AT 2 YEARS OF A PHASE II TRIAL
G Rosti, F Castagnetti, F Palandri, A Poerio, M Breccia, L Levato, A Capucci, M Tiribelli, A Zaccaria, T Intermesoli, B Martino, M Cedrone, G Gugliotta, M Amabile, N Testoni, G Alimena, F Pane, G Saglio, G Martinelli, M Baccarani (Dpt. of Hematology and Oncology „Seràgnoli„, Bologna, Italy)

PRELIMINARY RESULTS OF A PHASE II TRIAL OF LOW-DOSE CLOFARABINE IN COMBINATION WITH THE MTOR INHIBITOR TEMSIROLIMUS AS FIRST SALVAGE THERAPY FOR ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA (GIMEMA AML-1107)
S Amadori, A Venditti, A Martelli, E Ammatuna, G Meloni, L Pagano, G Saglio, M Lunghi, V Rizzoli, C Fozza, G Martinelli, E La Sala, P Fazi, M Vignetti (Tor Vergata University Hospital, Rome, Italy)

PP2A IMPAIRED ACTIVITY IS A COMMON EVENT IN ACUTE MYELOID LEUKEMIA, AND ACTIVATION BY FORSKOLIN TREATMENT INDUCES A POTENT ANTILEUKEMIC EFFECT
I Cristóbal, L García-Ortí, L Urquiza, M Alonso, E Bandrés, MJ Calasanz, MD Odero (CIMA, University of Navarra, Pamplona, Spain)

AC220, A POTENT, SELECTIVE, SECOND GENERATION FLT3 RECEPTOR TYROSINE KINASE (RTK) INHIBITOR, IN A FIRST-INHUMAN PHASE 1 AML STUDY
M Trikha, J Cortes, J Foran, D Ghirdaladze, M DeVetten, M Zodelava, P Holman, M Levis, H Kantarjian, G Borthakur, J James, R Armstrong, P Zarrinkar, N Padre, W Wierenga, R Corringham (Ambit Biosciences, San Diego, USA)

INDUCTION OF COMPLETE AND MOLECULAR REMISSIONS IN ACUTE MYELOID LEUKEMIA BY WILMS' TUMOR 1 ANTIGENTARGETED DENDRITIC CELL VACCINATION
N. Berneman, A van de Velde, S Anguille, A van Driessche, N Cools, K Vermeulen, K Pieters, G Nijs, B Stein, W Schroyens, A Gadisseur, I Vrelust, J de Vries, Y Oji, Y Oka, H Sugiyama, V van Tendeloo (Antwerp University Hospital (UZA), Edegem, Belgium)

LONG-TERM OUTCOMES OF RESPONDERS IN A RANDOMIZED, CONTROLLED PHASE II TRIAL OF APTAMER AS1411 IN AML
R Stuart, K Stockerl-Goldstein, A Wei, R Herzig, F Erlandsson, D Rizzieri (Medical University of South Carolina, Charleston, USA)

INHIBITION OF HISTONE DEACETYLASE ACTIVITY SUPPRESSES THE 60S SUBUNIT MATURATION DEFECT IN A YEAST MODEL OF SHWACHMAN DIAMOND SYNDROME
S Ellis, J Moore (University of Louisville, Louisville, USA)

ABNORMAL TELOMERE SHORTING IN PERIPHERAL BLOOD MONONUCLEAR CELLS AND GRANULOCYTES OF PATIENTS WITH CHRONIC IDIOPATHIC NEUTROPENIA
K Pavlaki, MC Kastrinaki, K Pyrovolaki, I Mavroudi, G Gvazava, E Stavroulaki, S Mastrodemou, H Papadaki (University of Crete School of Medicine, Heraklion, Greece)

MECHANISTIC INSIGHT INTO THE NAMPT / SIRT1 MEDIATED DOWN REGULATION OF P53 AND FOXO3A LEADING TO IMPAIRMENT OF GENES INVOLVED IN CELL CYCLE REGULATION AND DNA DAMAGE REPAIR
B Thakur, Y Lippka, T Dittrich, J Skokowa, K Welte (Hannover Medical School, Hannover, Germany)

THE RISK OF LEUKEMIA IN GENETIC SUBGROUPS OF CONGENITAL NEUTROPENIA
C Zeidler, A Bolyard, P Vandenberghe, G Pracht, L Hoy, M Zimmermann, D Link, C Klein, M Germeshausen, D Dale, K Welte (SCNIR, Hannover, Germany)

INHIBITION OF THE NAMPT/SIRT2 PATHWAY LEADS TO THE REDUCED PROLIFERATION AND INCREASE APOPTOSIS OF THE ACUTE LEUKEMIA CELLS VIA MODULATION OF THE AKT/GSK3ß PATHWAY
D Lan, A Gigina, K Welte, J Skokowa (Hannover Medical School, Hannover, Germany)

HIGH DOSE THERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION IN FIRST RELAPSE FOR DLBCL STILL IMPROVES PROGRESSION FREE SURVIVAL IN THE RITUXIMAB ERA. A RETROSPECTIVE ANALYSIS OF THE EBMT-LWP
C Gisselbrecht, C Canals, N Mounier, R Foà, E Conde, J Maertens, A Rambaldi, T Masszi, JJ Luan, C Crawley, G Cook, M Attal, M Pfreundschuh, JL Harousseau, A Sureda (Hôpital St. Louis, Paris, France)

CONSTITUTIONAL VARIABILITY IN GENES INVOLVED IN INNATE IMMUNITY AND IN CELL PROLIFERATION INFLUENCES DISEASE FREE SURVIVAL AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
B Martin-Antonio, R Cardesa, I Alvarez, F Marquez-Malaver, P Trujillo, M Carmona, J Falantes, I Espigado, A Urbano-Ispizua (Hospital Universitario Virgen del Rocio, Sevilla, Spain)

A NOVEL HIGH DOSE CHEMOTHERAPY STRATEGY WITH BENDAMUSTINE IN ADJUNCT TO ETOPOSIDE, ARACYTIN AND MELPHALAN (BEEAM) FOLLOWED BY AUTOLOGOUS STEM CELL RESCUE IS SAFE AND HIGHLY EFFECTIVE FOR THE TREATMENT OF RESISTANT/RELAPSED LYMPHOMA PATIENTS: A PHASE I-II STUDY ON 33 PATIENTS
G Visani, L Malerba, P Stefani, S Capria, P Galieni, F Gaudio, G Specchia, G Meloni, F Gherlinzoni, C Giardini, S Falcioni, F Loscocco, F Cuberli, M Gobbi, B Sarina, A Santoro, M Rocchi, A Isidori (Hematology and Stem Cell Transplant Center, Pesaro, Italy)

ACUTE LYMPHOBLASTIC LEUKAEMIA IN CHILDHOOD: OUTCOMES OF UNRELATED CORD BLOOD TRANSPLANT
A Ruggeri, JH Dalle, G Michel, N Kabbara, D Purtill, C Díaz de Heredia, AP Iori, M Diaz, M Mauad, A Verdeguer, T O’Brien, F Locatelli, C Peters, E Gluckman, V Rocha (Eurocord-Hopital Saint Louis, Paris, France)

LATE PROPHYLACTIC DONOR LYMPHOCYTE INFUSIONS IN HIGH RISK ACUTE LEUKEMIAS
M Stadler, E Dammann, S Buchholz, H Diedrich, H Kamal, A Breithaupt, E Mischak-Weissinger, B Hertenstein, M Eder, J Krauter, A Ganser (Hannover Medical School, Hannover, Germany)

CLINICAL ACTIVITY IN A PHASE 1 STUDY OF CAL-, AN ISOFORMSELECTIVE INHIBITOR OF PHOSPHATIDYLINOSITOL 3-KINASE P110DELTA, IN PATIENTS WITH B-CELL MALIGNANCIES
J Brown, J Byrd, R Furman, I Flinn, D Benson, S Coutre, B Kahl, N Wagner- Johnston, S Spurgeon, K Pratz, N Giese, A Yu (Dana-Farber Cancer Institue, Boston, USA)

A PHASE I/II STUDY OF IPH, GAMMA DELTA T CELL AGONIST, IN COMBINATION WITH RITUXIMAB RE-TREATMENT, IN PATIENTS WITH LOW GRADE FOLLICULAR LYMPHOMA
JF Rossi, P Solal-Celigny, P Soubeyran, V Delvail, H Ghesquieres, C Thieblemont, E Jourdan, V Kunzmann, P Feugier, RO Casasnovas, S Le Gouill, E van den Neste, S Lafaye De Micheaux, M Marzetto, L Beautier, P Squiban, H Sicard, G Laurent (Hospital Lapeyronie, Montpellier, France)

PBI-1402: A FIRST-IN-CLASS ERYTHROPOIESIS-STIMULATING AGENT (ESA) WHICH REDUCES THE NEED FOR BLOOD TRANSFUSION IN CHEMOTHERAPY-INDUCED (CIA) ANEMIC PATIENTS
L Gagnon, J Barabé, C Penney, V Kovcin, S Bosˇnjak, P Laurin (ProMetic BioSciences Inc., Laval, Canada)

ANTITUMOR ACTIVITY OF THE INVESTIGATIONAL DRUG MLN970, A SECOND-GENERATION PROTEASOME INHIBITOR, IN PRECLINICAL MODELS OF DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
A Berger, J Donelan, E Lee, B Bannerman, K Bano, T Babcock, Y Cao, M Fitzgerald, P Hales, E Koenig, E Lightcap, A Mazzola, P Smith, B Stringer, Y Yang, J Yu, J Zhang, P Fleming, E Kupperman (Millennium Pharmaceuticals, Inc., Cambridge, USA)

LEUKEMIC CD52 NEGATIVE GPI DEFECTIVE CLONES ARE COMMON IN ALL, ESCAPE ALEMTUZUMAB THERAPY, BUT ARE SENSITIVE TO RITUXIMAB MEDIATED COMPLEMENT DEPENDENT CYTOTOXICITY: RATIONALE FOR COMBINATION THERAPY
B Nijmeijer, M van Schie, H Goselink, C Halkes, J Falkenburg (Leiden University Medical Center, Leiden, The Netherlands)

PLERIXAFOR TARGETS PRIMARY CHRONIC MYELOID LEUKAEMIA STEM/PROGENITOR CELLS AND ENHANCES THEIR SENSITIVITY TO TYROSINE KINASE INHIBITORS
J Richmond, M Copland (University of Glasgow, Glasgow, United Kingdom)

SAFETY AND EFFICACY OF SECOND-LINE BOSUTINIB (SKI-606) IN IMATINIB RESISTANT OR INTOLERANT CHRONIC PHASE (CP) CHRONIC MYELOID LEUKEMIA (CML)
T Brümmendorf, J Cortes, A Turkina, T Masszi, S Assouline, S Durrant, A Volkert, J Wang, S Arkin, C Gambacorti-Passerini (Universitäts-Klinikum Hamburg-Eppendorf & Universitätsklinikum Aachen, Aachen, Germany)

LONG-LASTING P210 PEPTIDE VACCINE TREATMENT IN CHRONIC MYELOID LEUKEMIA PATIENTS: SAFETY PROFILE AND CLINICAL RESULTS
M Defina, M Ippoliti, A Gozzetti, R Crupi, L Aprile, M Tassi, M Rondoni, F Lauria, M Bocchia (Hematology and Transplants, Siena, Italy)

NILOTINIB INDUCES RAPID AND DURABLE RESPONSES WITH 24-MONTH MINIMUM FOLLOW-UP IN PATIENTS WITH IMATINIBRESISTANT OR -INTOLERANT CHRONIC MYELOID LEUKEMIA IN BLAST CRISIS (CML-BC)
F Giles, H Kantarjian, P le Coutre, M Baccarani, R Blakesley, N Gallagher, K Gillis, R Larson, O Ottmann (CTRC at The UT Health Science Center, The Institute for Drug Development, San Antonio, USA)

EARLY CYTOGENETIC AND MOLECULAR RESPONSES AND PHARMACOKINETIC OF DASATINIB AS A FIRST LINE THERAPY IN NEWLY DIAGNOSED CHRONIC PHASE CML PATIENTS: FIRST ANALYSIS OF THE OPTIM DASATINIB TRIAL
P Rousselot, S Bouchet, G Etienne, F Nicolini, E Chauzit, P Cony Makhoul, V Coiteux, A Guerci-Bresler, M Gardembas-Pain, L Legros, L Roy, C Dartigeas, M Janvier, C Berthou, M Molimard, J Guilhot, F Guilhot, FX Mahon (Hôpital Mignot, Université de Versailles, Le Chesnay, France)

PATTERNS OF SURVIVAL AMONG 7,249 PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS DIAGNOSED IN SWEDEN 1973-2003
L Hultcrantz, S Kristinsson, T Andersson, S Eloranta, A Derolf, O Landgren, P Dickman, M Björkholm (Karolinska Institutet, Stockholm, Sweden)

THE JAK2 46/1 (GGCC) HAPLOTYPE IS ASSOCIATED WITH PRIMARY MYELOFIBROSIS INDEPENDENTLY OF V617F MUTATIONAL STATUS, DISEASE CHARACTERISTICS OR PROGNOSIS
M. Vannucchi, P Guglielmelli, F Biamonte, A Spolverini, A Pancrazzi, L Pieri, A Isgrò, E Antonioli, N Bartalucci, A Bosi, G Barosi (University of Florence, Florence, Italy)

MUTATIONS OF IDH1 AND IDH2 IN MYELOPROLIFERATIVE NEOPLASMS: ASSOCIATION WITH LEUKEMIC TRANSFORMATION
F Stegelmann, P Paschka, M Griesshammer, C Blersch, S Kuhn, S Schauer, H Döhner, K Döhner (University Hospital of Ulm, Ulm, Germany)

EVIDENCE OF EFFICACY OF RAD00, AN INHIBITOR OF MTOR, IN A PHASE I/II STUDY IN PRIMARY MYELOFIBROSIS (PMF) AND POST POLYCYTHEMIA VERA/ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (PPV/PET MF)
M. Vannucchi, P Guglielmelli, L Lupo, MC Finazzi, L Tozzi, F Biamonte, E Antonioli, C Bogani, L Pieri, E Gattoni, A Masciulli, S Paratore, MC Susini, G Finazzi, R Marchioli, A Rambaldi, T Barbui, A Bosi, G Barosi (University of Florence, Florence, Italy)

FIRST REPORT OF THE PHASE-I STUDY OF THE NOVEL ORAL JAK2 INHIBITOR SB1518 IN PATIENTS WITH MYELOFIBROSIS
F Seymour, B To, A Goh, L Meadows, A Ethirajulu, A Wood, A Zhu, W Roberts (Peter MacCallum Cancer Centre, East Melbourne, Australia)

TWO CYCLES OF ABVD FOLLOWED BY INVOLVED FIELD RADIOTHERAPY WITH 20 GRAY (GY) IS THE NEW STANDARD OF CARE IN THE TREATMENT OF PATIENTS WITH EARLY-STAGE HODGKIN LYMPHOMA: FINAL ANALYSIS OF THE RANDOMIZED GERMAN HODGKIN STUDY GROUP (GHSG) HD10 STUDY
A Engert, A Pluetschow, H Eich, R Herrmann, B Doerken, L Kanz, R Greil, J Markova, M Fuchs, P Borchmann, H Mueller-Hermelink, R Mueller, V Diehl (University Hospital Cologne, Cologne, Germany)

DACARBAZINE IS AN ESSENTIAL COMPONENT OF ABVD IN THE TREATMENT OF EARLY FAVOURABLE HODGKIN LYMPHOMA: RESULTS OF THE SECOND INTERIM ANALYSIS OF THE GHSG HD13 TRIAL
P Borchmann, V Diehl, H Goergen, A Lohri, J Zijlstra, M Topp, M Fuchs, H Eich, A Engert (Uniklinik Köln, Köln, Germany)

EVIDENCE OF CLINICAL ACTIVITY IN A PHASE II STUDY OF ORAL PANOBINOSTAT IN PATIENTS WITH RELAPSED/ REFRACTORY HODGKIN LYMPHOMA (HL) AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT (AHSCT)
A Engert, A Sureda, C Chiattone, V Buccheri, TC Ong, D Ben-Yehuda, N Myke, A Shen, C Le Corre, A Younes (Klinikum der Universität zu Köln, Cologne, Germany)

INCREASED EXPRESSION OF CD4+CD25+FOXP3+ REGULATORY T CELLS PREDICTS POOR RESPONSE AND CORRELATES WITH EPSTEIN-BARR VIRUS PRESENCE IN REED-STERNBERG CELLS IN PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA
M Assis, A Campos, F Soares, J Silva, P Brito, E Souza, J Oliveira, O Baiocchi (Oncology Department, Federal University of Sao Paulo, Sao Paulo, Brazil)

EARLY FDG-PET SCAN CONFIRMS ITS PROGNOSTIC IMPACT ALSO IN LOCALIZED STAGE, ABVD TREATED HODGKIN LYMPHOMA PATIENTS
L Rigacci, PL Zinzani, B Puccini, A Broccoli, A Gallamini, F Merli, G Antognoli, V Stefoni, C Stelitano, M Balzarotti, P Pregno, C Fraulini, F Salvi, R Emili, S Tavera, I Capodanno, U Vitolo, C Pellegrini, AM Liberati, A Bosi (Azienda Ospedaliera Careggi, Florence, Italy)

VCAM1 RS1041163 POLYMORPHISM INFLUENCES G-CSF MOBILIZATION OF CD34+ CELLS
B Martin-Antonio, M Carmona, A Baez, P Trujillo, J Falantes, I Espigado, A Urbano-Ispizua (Hospital Universitario Virgen del Rocio, Sevilla, Spain)

POLYMORPHISMS OF THE HEPARANASE GENE (HPSE) ARE ASSOCIATED WITH THE INCIDENCE AND SEVERITY OF GRAFT VS. HOST DISEASE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
O Ostrovsky, A Shimoni, I Vlodavsky, A Nagler (Chaim Sheba Medical Center, Ramat Gan, Israel)

RESISTANCE OF AGGRESSIVE MINOR CML BLAST SUBSET TOWARD BOTH IMATINIB AND NK-CELLS KILLING CAN BE REVERSED BY PGP- MODULATORS
H Galski, S Berlinsky, M Simanovsky, T Oved-Gelber, A Nagler (Chaim Sheba Medical Center, Tel Hashomer, Israel)

QUIESCENT LEUKEMIC STEM CELLS RESIDING AFTER TYROSINE KINASE INHIBITOR TREATMENT ARE NOT TARGETED BY ALLOREACTIVE T CELLS AND NK CELLS
I Jedema, L van Dreunen, J Falkenburg (Leiden University Medical Center, Leiden, The Netherlands)11:30 – 11:45

VACCINATION WITH DENDRITIC CELLS LOADED WITH APOPTOTIC BODIES (APO-DC) OF AUTOLOGOUS LEUKEMIC CELLS INDUCES IMMUNOLOGIC RESPONSES IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS
L Hansson, M Palma, L Adamson, I Eriksson, B Näsman-Glaser, P Kokhaei, K Widen, A Choudhury, A Österborg, H Mellstedt (Karolinska Institutet, Stockholm, Sweden)

ETO2 CONTROLS HEMATOPOIETIC STEM CELL EXPANSION VIA THE NERVY HOMOLOGY DOMAIN 1
S Barakat, J Lambert, G Sauvageau, T Hoang (IRIC, Montreal, Canada)

DNA DAMAGE FROM STALLED REPLICATION IN HEMATOPOIETIC STEM CELLS LEADS TO P53-DEPENDENT BONE MARROW FAILURE THAT PREVENTS LEUKEMIC OUTGROWTH
J Haanstra, J Verhagen-Oldenampsen, P van Strien, M Valkhof, B Schumacher, I Touw, M Von Lindern (ErasmusMC, Rotterdam, The Netherlands)

MEGAKARYOCYTES SUPPORT THE INTEGRITY OF BONE MARROW (BM) VASCULAR NICHES AND ATTRACT METASTATIC TUMOUR CELLS TO THE BM IN MURINE MODELS OF METASTASIS AND IN PATIENTS WITH CARCINOMA
B Psaila, S Lavotshkin, J Podolanczuk, S Granitto, M Papaspyridonos, N Kaplan, B Bussel, N Kikkeri, I Roberts, D Lyden (Imperial College, London, London, United Kingdom)

THE CDK-INHIBITOR P26INCA1 IS REQUIRED FOR THE MAINTENANCE OF MYELOID LEUKEMIA STEM CELL SELFRENEWAL
P Tschanter, N Bäumer, L Lohmeyer, F Berkenfeld, L Tickenbrock, S Diederichs, M Stehling, G Köhler, W Berdel, S Koschmieder, C Müller- Tidow (University of Münster, Germany, Münster, Germany)

THE EMT INDUCER SIP1/ZEB2 IS ESSENTIAL FOR DEFINITIVE EMBRYONIC HEMATOPOIESIS
S Goossens, T Yokomizo, B Drogat, S Bartunkova, K Haigh, E Seuntjens, M Crisan, T Riedt, G Berx, E Dzierzak, V Janzen, D Huylebroeck, J Haigh (University Ghent, VIB, Gent (Zwijnaarde), Belgium)

VASCULAR PROGENITOR CELLS CAN INSTRUCT DEVELOPMENTAL FATE DECISION OF CD146+ MESENCHYMAL STROMAL / STEM CELLS IN VIVO
A Reinisch, N Hofmann, A Ortner, N Etchart, C Beham-Schmid, C Dullin, C Diwoky, A Hofmeister, R Stollberger, F Alves, D Strunk (Medical University of Graz, Graz, Austria)

DIFFERENCES IN ALLOREACTIVE T CELL MIGRATION IN MHC MATCHED VERSUS MHC MISMATCHED HCT ARE CAUSED BY WAVES OF T CELL EXPANSION
C Bäuerlein, S Riedel, C Brede, AL Jordán Garrote, C Kiesel, M Ritz, S Schulz, M Grether, G Beilhack, R Negrin, H Einsele, A Beilhack (University Hospital Würzburg, Würzburg, Germany)

FUNCTIONAL IMMUNE RECOVERY AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: NASCENT DONOR T CELLS ARE SUPERIOR TO MATURE GRAFT T CELLS IN THEIR REACTIVITY AGAINST CYTOMEGALOVIRUS
A Mueller, S Shashidhar, J Brown, J Shizuru (Stanford School of Medicine, Stanford, USA)

CD11B+CD11C+ DENDRITIC CELLS INTERACT WITH ALLOREACTIVE T CELLS IN THE INTESTINAL MUCOSA IN ACUTE GRAFT-VERSUS-HOST DISEASE
AL Jordán Garrote, C Brede, C Baeuerlein, S Riedel, C Kiesel, M Grether, K Mattenheimer, M Ritz, J Baker, R Negrin, H Einsele, A Beilhack, S Schulz (Wuerzburg University, Wuerzburg, Germany)

UMBILICAL CORD BLOOD REGULATORY T CELLS: FUNCTIONAL ANALYSIS AND GENE PROFILING
G Torelli, R Maggio, N Peragine, S Chiaretti, M De Propris, M Screnci, B Lucarelli, M Mascolo, A Iori, G Girelli, A Guarini, R Foà (Sapienza University, Rome, Italy)

FURTHER STUDIES IN CEBPA DOUBLE MUTATIONS AS REGARDS TO FAVOURABLE PROGNOSTIC IMPACT, RELATION WITH OTHER GENE MUTATIONS AND IMPROVED GENE EXPRESSION SIGNATURE IN A LARGE COHORT OF AML
E Taskesen, L Bullinger, M Sanders, C Erpelinck, B Wouters, F Damm, J Krauter, R Schlenk, D Hartmut, B Löwenberg, R Delwel, P Valk, K Döhner (Erasmus Medical Centre (EMC), Rotterdam, The Netherlands)

PROGNOSTIC IMPORTANCE OF HUMAN MIXED LINEAGE LEUKEMIA 5 (MLL5) EXPRESSION LEVELS IN ACUTE MYELOID LEUKEMIA
F Damm, T Oberacker, J Krauter, M Morgan, K Wagner, F Thol, K Döhner, H Döhner, A Ganser, M Heuser (Hannover Medical School, Hannover, Germany)

SINGLE CELL NETWORK PROFILING (SCNP) OFFERS A NOVEL APPROACH TO IDENTIFY AT DIAGNOSIS AML CHEMOTHERAPY RESISTANT CELL PHENOTYPES
A Cesano, A Cohen, T Covey, S Putta, U Gayko, X Xiaohua, W Fantl, S Kornblau (Nodality, South San Francisco, USA)

A STUDY ON THE CLINICAL SIGNIFICANCE OF THE WHO AML SUBTYPE INV(3)(Q21Q26.2)/T(3;3)(Q21;Q26.2) AND VARIOUS OTHER 3Q CHROMOSOMAL ABNORMALITIES IN 6,819 AML CASES
S Lugthart, S Gröschel, H Beverloo, P Valk, U Schanz, S Bhola, E Vellenga, S Kayser, G Ossenkoppele, G Verhoef, A Ferrant, E van den Berg-de Ruiter, A Ganser, M Jotterand, J Krauter, T Pabst, B Schlegelberger, R Schlenk, R Delwel, K Döhner, B Löwenberg, H Döhner (Erasmus MC, Rotterdam, The Netherlands)

RUNX1 MUTATIONS FORM A DISTINCT MOLECULAR SUBGROUP IN ACUTE MYELOID LEUKEMIA: RESULTS OF THE AML STUDY GROUP (AMLSG)
V Gaidzik, L Bullinger, R Schlenk, A Zimmermann, J Röck, B Schlegelberger, J Krauter, A Ganser, D Späth, H Döhner, K Döhner (Universtiy Hospital of Ulm, Internal Medicine III, Ulm , Germany, Ulm, Germany)